Conference Coverage

One-month TB-prevention regimen effective in HIV+ individuals


 

REPORTING FROM CROI

BOSTON – A combination regimen of rifapentine­ plus isoniazid (1HP) can do in 1 month what it takes isoniazid monotherapy 9 months to accomplish: effectively prevent tuberculosis in persons with HIV infection, investigators in the randomized phase 3 BRIEF TB trial reported.

“Rates of tuberculosis or death in individuals on 1HP were essentially identical to the rates of tuberculosis or death in people who got the 9-months regimen,” said Richard Chaisson, MD, of Johns Hopkins University, Baltimore.

“People who got the 1-month regimen were more likely to complete it, had slightly less toxicity, and overall had very similar clinical outcomes,” he said at the annual Conference on Retroviruses & Opportunistic Infections.

Worldwide, more than 1,000 persons with HIV infection die from tuberculosis every day, he noted.

Pages

Recommended Reading

HHS creates new religious freedoms division
MDedge Family Medicine
Gene therapy moves from promise to reality
MDedge Family Medicine
Trial seeks improved regimens for pregnant women with HIV
MDedge Family Medicine
nPEP for HIV: Updated CDC guidelines available for primary care physicians
MDedge Family Medicine
FDA approves complete combo tablet for HIV
MDedge Family Medicine
FDA approves new combination drug for HIV patients
MDedge Family Medicine
Gut-homing protein predicts HIV-acquisition, disease progression in women
MDedge Family Medicine
Inflammatory markers predict vaccine response in HCV, HIV
MDedge Family Medicine
VIDEO: The return of Kaposi’s sarcoma
MDedge Family Medicine
Bloating. Flatulence. Think SIBO
MDedge Family Medicine